Exploring plant cells to find new ways to protect against neurodegenerative diseases.
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
This study is looking at how plant cells can help us understand the harmful effects of proteins linked to diseases like Alzheimer's and Parkinson's, with the hope of finding new ways to protect the brain and develop better treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Naprogenix, INC NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10469507 on NIH RePORTER |
What this research studies
This research investigates how plant cells can mimic the toxic effects of misfolded proteins associated with neurodegenerative diseases like Alzheimer's and Parkinson's. By transforming plant cells to express a variant of human alpha-synuclein, researchers aim to understand the mechanisms of neurotoxicity and identify potential neuroprotective compounds. The study involves selecting mutant plant cells that show resistance to this toxicity, which could lead to the discovery of new treatments for neurodegenerative conditions. Patients may benefit from the insights gained into neuroprotection and potential therapeutic leads derived from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with neurodegenerative diseases such as Alzheimer's or Parkinson's.
Not a fit: Patients with neurodegenerative diseases not related to protein misfolding may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel treatments that protect against neurodegenerative diseases.
How similar studies have performed: Other research has shown promise in using plant models to study neurodegeneration, indicating that this approach could yield valuable insights.
Where this research is happening
Lexington, United States
- Naprogenix, INC — Lexington, United States (Active)
Researchers
- Principal investigator: Huang, Chifu — Naprogenix, INC
- Study coordinator: Huang, Chifu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.